Selected article for: "model virus and rVSV vesicular stomatitis virus"
Author: Rhein, Bethany A.; Powers, Linda S.; Rogers, Kai; Anantpadma, Manu; Singh, Brajesh K.; Sakurai, Yasuteru; Bair, Thomas; Miller-Hunt, Catherine; Sinn, Patrick; Davey, Robert A.; Monick, Martha M.; Maury, Wendy
Title: Interferon-? Inhibits Ebola Virus Infection
  • Document date: 2015_11_12
    • ID: 10bu7iwg_5
    Snippet: Here, we demonstrate that IFNγ blocks EBOV infection of murine peritoneal macrophages and robustly protects mice from fatal EBOV infection when administered as late as 24 hours following infection. We also identified novel IFNγ-stimulated genes that inhibit EBOV infection, defining new downstream mechanisms through which this FDA-approved drug functions. During these studies, we evaluated IFNγ inhibition of a BSL2 model virus of EBOV, recombin.....
    Document: Here, we demonstrate that IFNγ blocks EBOV infection of murine peritoneal macrophages and robustly protects mice from fatal EBOV infection when administered as late as 24 hours following infection. We also identified novel IFNγ-stimulated genes that inhibit EBOV infection, defining new downstream mechanisms through which this FDA-approved drug functions. During these studies, we evaluated IFNγ inhibition of a BSL2 model virus of EBOV, recombinant vesicular stomatitis virus (VSV) encoding EBOV glycoprotein (EBOV GP/rVSV), in interferon α/β receptor knock out (IFNAR -/-) mice. IFNγ was highly effective at inhibiting infection by this recombinant virus. Comparative use of this recombinant BSL2 virus in parallel with EBOV and wild-type VSV permitted us to evaluate the mechanism of IFNγ inhibition in greater detail. These latter findings suggest that IFNγ may have efficacy not only against EBOV, but also a broader range of Mononegavirales.

    Search related documents:
    Co phrase search for related documents
    • broad range and great detail: 1
    • broad range and α interferon β receptor: 1
    • EBOV glycoprotein and fatal EBOV infection: 1
    • EBOV glycoprotein and α interferon β receptor: 1
    • EBOV GP rVSV EBOV glycoprotein and α interferon β receptor: 1
    • EBOV infection and fatal EBOV infection: 1, 2, 3
    • EBOV infection and α interferon β receptor: 1, 2
    • EBOV infection and IFNγ inhibition: 1, 2, 3
    • EBOV infection inhibit and IFNγ inhibition: 1
    • EBOV model virus and α interferon β receptor: 1
    • α interferon β receptor and IFNAR mouse: 1, 2